Neutralizing antibodies against the SARS-CoV-2 Omicron BA.1 variant following homologous and heterol...
Neutralizing antibodies against the SARS-CoV-2 Omicron BA.1 variant following homologous and heterologous CoronaVac or BNT162b2 vaccination
About this item
Full title
Author / Creator
Journal title
Language
English
Formats
More information
Scope and Contents
Contents
The Omicron variant is rapidly becoming the dominant SARS-CoV-2 virus circulating globally. It is important to define reductions in virus neutralizing activity in serum of convalescent or vaccinated individuals to understand potential loss of protection against infection by Omicron. We have previously established that a 50% plaque reduction neutral...
Alternative Titles
Full title
Neutralizing antibodies against the SARS-CoV-2 Omicron BA.1 variant following homologous and heterologous CoronaVac or BNT162b2 vaccination
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8940714
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8940714
Other Identifiers
ISSN
1078-8956
E-ISSN
1546-170X
DOI
10.1038/s41591-022-01704-7
